196 related articles for article (PubMed ID: 9465021)
1. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.
Moasser MM; Sepp-Lorenzino L; Kohl NE; Oliff A; Balog A; Su DS; Danishefsky SJ; Rosen N
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1369-74. PubMed ID: 9465021
[TBL] [Abstract][Full Text] [Related]
2. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells.
Sepp-Lorenzino L; Rosen N
J Biol Chem; 1998 Aug; 273(32):20243-51. PubMed ID: 9685373
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
4. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
5. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
Bolick SC; Landowski TH; Boulware D; Oshiro MM; Ohkanda J; Hamilton AD; Sebti SM; Dalton WS
Leukemia; 2003 Feb; 17(2):451-7. PubMed ID: 12592346
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel.
Nakamura K; Yamaguchi A; Namiki M; Ishihara H; Nagasu T; Kowalczyk JJ; Garcia AM; Lewis MD; Yoshimatsu K
Oncol Res; 2001; 12(11-12):477-84. PubMed ID: 11939411
[TBL] [Abstract][Full Text] [Related]
7. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao TP; Khuri FR; Giannakakou P
Cancer Res; 2005 May; 65(9):3883-93. PubMed ID: 15867388
[TBL] [Abstract][Full Text] [Related]
8. Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression.
Doisneau-Sixou SF; Cestac P; Faye JC; Favre G; Sutherland RL
Int J Cancer; 2003 Sep; 106(5):789-98. PubMed ID: 12866041
[TBL] [Abstract][Full Text] [Related]
9. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells.
Crespo NC; Ohkanda J; Yen TJ; Hamilton AD; Sebti SM
J Biol Chem; 2001 May; 276(19):16161-7. PubMed ID: 11154688
[TBL] [Abstract][Full Text] [Related]
10. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
[TBL] [Abstract][Full Text] [Related]
11. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
Tamanoi F; Gau CL; Jiang C; Edamatsu H; Kato-Stankiewicz J
Cell Mol Life Sci; 2001 Oct; 58(11):1636-49. PubMed ID: 11706990
[TBL] [Abstract][Full Text] [Related]
12. K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells.
Song SY; Meszoely IM; Coffey RJ; Pietenpol JA; Leach SD
Neoplasia; 2000; 2(3):261-72. PubMed ID: 10935512
[TBL] [Abstract][Full Text] [Related]
13. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
Morgan MA; Wegner J; Aydilek E; Ganser A; Reuter CW
Leukemia; 2003 Aug; 17(8):1508-20. PubMed ID: 12886237
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.
Shi Y; Gera J; Hsu JH; Van Ness B; Lichtenstein A
Mol Cancer Ther; 2003 Jun; 2(6):563-72. PubMed ID: 12813136
[TBL] [Abstract][Full Text] [Related]
15. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor.
van Golen KL; Bao L; DiVito MM; Wu Z; Prendergast GC; Merajver SD
Mol Cancer Ther; 2002 Jun; 1(8):575-83. PubMed ID: 12479217
[TBL] [Abstract][Full Text] [Related]
16. The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.
Ashar HR; James L; Gray K; Carr D; McGuirk M; Maxwell E; Black S; Armstrong L; Doll RJ; Taveras AG; Bishop WR; Kirschmeier P
Exp Cell Res; 2001 Jan; 262(1):17-27. PubMed ID: 11120601
[TBL] [Abstract][Full Text] [Related]
17. Pamidronate, farnesyl transferase, and geranylgeranyl transferase-I inhibitors affects cell proliferation, apoptosis, and OPG/RANKL mRNA expression in stromal cells of giant cell tumor of bone.
Lau CP; Huang L; Tsui SK; Ng PK; Leung PY; Kumta SM
J Orthop Res; 2011 Mar; 29(3):403-13. PubMed ID: 20886653
[TBL] [Abstract][Full Text] [Related]
18. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
[TBL] [Abstract][Full Text] [Related]
19. The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer.
Moasser MM; Rosen N
Breast Cancer Res Treat; 2002 May; 73(2):135-44. PubMed ID: 12088116
[TBL] [Abstract][Full Text] [Related]
20. Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?
O'Regan RM; Khuri FR
Endocr Relat Cancer; 2004 Jun; 11(2):191-205. PubMed ID: 15163298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]